Azalea Therapeutics

Azalea Therapeutics is a biotechnology company redefining in vivo precision genomic medicines. Its proprietary Enveloped Delivery Vehicle (EDV) platform is designed to deliver transient CRISPR-Cas9 cargoes to specific cells within the body for site-specific genome editing with therapeutic intent. Azalea’s initial programs leverage T cell-targeting EDVs and highly efficient T cell-tropic AAVs to achieve programmable CAR gene insertion at defined genomic sites, enabling expression controlled by the physiological and sustained activity of endogenous promoters within the cell. This approach aims to directly generate potent, durable, and safe therapies within patients, bypassing the complexities of ex vivo manufacturing and unlocking new therapeutic modalities—including in vivo CAR-T cell therapies—spanning cancer, autoimmune diseases, and genetic disorders.